|
|
|
|
|
|
|
EXPERT-LED JOURNAL CLUB DISCUSSIONS |
|
|
|
|
|
| Optimal Treatment for Poor Prognosis Metastatic Castration-Resistant Prostate Cancer, Cabazitaxel vs Abi/Enza, Journal Club |
Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
Christopher Wallis and Zachary Klaassen discuss the Annals of Oncology article titled “Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial.” |
|
|
|
|
|
|
|
|
| Safety and Activity of Alpha-Emitting Ac-225-PSMA-617 Radioligand Therapy in mCRPC That Has Progressed After Lu-177-PSMA, Journal Club |
| Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen discuss a publication on the activity and adverse effects of Actinium-225 therapy, in advanced metastatic castrate resistant prostate cancer (mCRPC) patients, after the failure of their Lutetium-177 treatment. Following the introduction of specific PSA response data, an interesting trend is shown which shows patients who had no response to Lutetium treatment having a strong response to the Actinium treatment. |
|
|
|
|
|
|
|
|
|
|
| The Clinical Trial Protocol of UpFront PSMA, Phase 2 Study of Sequential 177Lu‐PSMA‐617 and Docetaxel vs Docetaxel in Metastatic Hormone‐Naïve Prostate Cancer, Journal Club
|
| Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen discuss a recent paper entitled, “UpFront PSMA: A Randomized Phase II Study of Sequential 177Lu-PSMA-617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naïve Prostate Cancer, a Clinical Trial Protocol.”
|
|
|
|
|
|
| The Role of Screening MRI To Detect Radiologic Evidence of Spinal Cord Compression With Subsequent Pre-Emptive Treatment in Men With Metastatic Castration-Resistant Prostate Cancer, Journal Club |
| Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
|
| Drs Christopher Wallis and Zachary Klaassen present a Lancet Oncology publication titled Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial. |
|
|
|
|
|
 |
|
|
|
|
|
